ONCODES.PREC.MED. EO-34 (ZR8) — Working Capital to Net Assets Ratio
ONCODES.PREC.MED. EO-34 (ZR8) has a Working Capital to Net Assets ratio of -1178.1% as of December 2024. Working capital of €5.06 Million (current assets of €8.67 Million minus current liabilities of €3.61 Million) is measured against net assets of €-429.39K. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ONCODES.PREC.MED. EO-34 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ONCODES.PREC.MED. EO-34 Working Capital to Net Assets (2021–2024)
This chart shows how ONCODES.PREC.MED. EO-34's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at -1178.1%, reflecting working capital of €5.06 Million against net assets of €-429.39K EUR. See ONCODES.PREC.MED. EO-34 (ZR8) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for ONCODES.PREC.MED. EO-34 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for ONCODES.PREC.MED. EO-34 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see ONCODES.PREC.MED. EO-34 market cap and net worth.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -1178.1% | €5.06 Million | €-429.39K | €8.67 Million | €3.61 Million | ▼ -1456.9 pp |
| 2023 | 278.8% | €10.29 Million | €3.69 Million | €14.40 Million | €4.11 Million | ▲ +173.2 pp |
| 2022 | 105.6% | €12.45 Million | €11.78 Million | €16.41 Million | €3.96 Million | ▼ -21.0 pp |
| 2021 | 126.6% | €5.32 Million | €4.20 Million | €6.53 Million | €1.21 Million | — |